STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
- PMID: 33359090
- DOI: 10.1053/j.gastro.2020.12.031
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Abstract
Background: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) has proposed treatment targets in 2015 for adult patients with inflammatory bowel disease (IBD). We aimed to update the original STRIDE statements for incorporating treatment targets in both adult and pediatric IBD.
Methods: Based on a systematic review of the literature and iterative surveys of 89 IOIBD members, recommendations were drafted and modified in 2 surveys and 2 voting rounds. Consensus was reached if ≥75% of participants scored the recommendation as 7 to 10 on a 10-point rating scale.
Results: In the systematic review, 11,278 manuscripts were screened, of which 435 were included. The first IOIBD survey identified the following targets as most important: clinical response and remission, endoscopic healing, and normalization of C-reactive protein/erythrocyte sedimentation rate and calprotectin. Fifteen recommendations were identified, of which 13 were endorsed. STRIDE-II confirmed STRIDE-I long-term targets of clinical remission and endoscopic healing and added absence of disability, restoration of quality of life, and normal growth in children. Symptomatic relief and normalization of serum and fecal markers have been determined as short-term targets. Transmural healing in Crohn's disease and histological healing in ulcerative colitis are not formal targets but should be assessed as measures of the remission depth.
Conclusions: STRIDE-II encompasses evidence- and consensus-based recommendations for treat-to-target strategies in adults and children with IBD. This frameworkshould be adapted to individual patients and local resources to improve outcomes.
Keywords: Biologics; Biomarkers; Endoscopic Healing; Patient-Reported Outcomes; Treat-to-Target.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD.Gastroenterology. 2021 Apr;160(5):1452-1460.e21. doi: 10.1053/j.gastro.2020.10.065. Epub 2021 Jan 6. Gastroenterology. 2021. PMID: 33421515
-
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.Am J Gastroenterol. 2015 Sep;110(9):1324-38. doi: 10.1038/ajg.2015.233. Epub 2015 Aug 25. Am J Gastroenterol. 2015. PMID: 26303131 Review.
-
Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges.Aliment Pharmacol Ther. 2023 Sep;58(5):492-502. doi: 10.1111/apt.17622. Epub 2023 Jun 29. Aliment Pharmacol Ther. 2023. PMID: 37382397 Review.
-
Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last.Gastroenterology. 2022 Apr;162(5):1424-1438. doi: 10.1053/j.gastro.2021.09.076. Epub 2022 Jan 4. Gastroenterology. 2022. PMID: 34995529
-
Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?World J Gastroenterol. 2015 Oct 28;21(40):11469-80. doi: 10.3748/wjg.v21.i40.11469. World J Gastroenterol. 2015. PMID: 26523111 Free PMC article. Review.
Cited by
-
Pro-motility Preparation Protocol May Reduce the Rates of Failed Patency Capsule Among Patients with Crohn's Disease in Clinical Remission.Dig Dis Sci. 2024 Oct 9. doi: 10.1007/s10620-024-08670-9. Online ahead of print. Dig Dis Sci. 2024. PMID: 39384710
-
Predicting mucosal inflammation in IBD patients using patient-reported symptom scores and a faecal calprotectin home test: protocol for a multicentre prospective validation study.BMJ Open. 2024 Oct 7;14(10):e076290. doi: 10.1136/bmjopen-2023-076290. BMJ Open. 2024. PMID: 39375184 Free PMC article.
-
Traditional Chinese medicine for functional gastrointestinal disorders and inflammatory bowel disease: narrative review of the evidence and potential mechanisms involving the brain-gut axis.Front Pharmacol. 2024 Sep 17;15:1444922. doi: 10.3389/fphar.2024.1444922. eCollection 2024. Front Pharmacol. 2024. PMID: 39355776 Free PMC article. Review.
-
Predictors of the efficacy of vedolizumab in patients with ulcerative colitis.Nagoya J Med Sci. 2024 Aug;86(3):407-421. doi: 10.18999/nagjms.86.3.407. Nagoya J Med Sci. 2024. PMID: 39355361 Free PMC article.
-
Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.World J Gastroenterol. 2024 Sep 14;30(34):3929-3931. doi: 10.3748/wjg.v30.i34.3929. World J Gastroenterol. 2024. PMID: 39350781 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials